Is Pfizer's Partner BioNTech About to Make a Big Blunder?

BioNTech (NASDAQ: BNTX) just might be the most underappreciated biotech on the planet. The German company initially developed the COVID-19 vaccine that caught Pfizer's (NYSE: PFE) attention. Many people now refer to that vaccine as "the Pfizer vaccine," completely leaving BioNTech out.

However, BioNTech has profited just as much as Pfizer has from the success of their COVID-19 vaccine. In the first quarter, the company recorded sales of 2.05 billion euros, with more than half of that amount flowing to its bottom line.

The big bucks are only beginning to flow in for BioNTech. Wall Street analysts project the company could rake in close to $15 billion this year. BioNTech will be flush with cash that it could use in lots of different ways. But is the biotech about to make a big blunder with one alternative that it's considering?

Source Fool.com